Importantly, it has been shown that the up-regulation of Mef2 is implicated in the cardiac hypertrophy and dilation (Molkentin and Markham, 1993; Xu et al., 2006), which is the major cause of death in FRDA patients. Here, MEF2A is linked to cardiac hypertrophy.